Sol-Gel Technologies
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Public
- Established
- 1997-01-01
- Employees
- 36
- Market Cap
- -
- Website
- http://www.sol-gel.com
- Introduction
Sol-Gel Technologies Ltd. operates as a clinical-stage dermatology company, which engages in the identification, development, and commercialization of topical dermatological drug products for the treatment of skin diseases. Its products include VERED, TWIN, and SIRS-T. The company was founded by David Avnir and Alon Seri-Levy on October 28, 1997 and is headquartered in Ness Ziona, Israel.
Sol-Gel and Mayne Pharma Announce $16 Million Deal for EPSOLAY and TWYNEO Rights in the U.S.
• Sol-Gel Technologies has entered into a $16 million agreement with Mayne Pharma for the sale and exclusive license of U.S. rights to dermatology products EPSOLAY and TWYNEO, extending the company's cash runway into Q1 2027.
• The transaction allows Sol-Gel to focus resources on its promising SGT-610 program for Gorlin syndrome, which has completed 80% patient recruitment for Phase III trials with top-line results expected in Q4 2026.
• Based on recent market research, Sol-Gel estimates SGT-610's U.S. market potential between $400-500 million annually as the first potential preventative treatment for basal cell carcinomas in Gorlin syndrome patients.
© Copyright 2025. All Rights Reserved by MedPath